Optimization of the Central Core of Indolinone–Acetic Acid-Based CRTH2 (DP2) Receptor Antagonists

Stefano Crosignani, Catherine Jorand‐Lebrun, Patrick Page, Gordon Campbell, V. Colovray, Marc Missotten, Yves Humbert, Christophe Cleva, Jean‐François Arrighi, Marilène Gaudet,

ACS Medicinal Chemistry Letters · 2011 · 65 citations · 14 references

DOIFull text

Open access

Concepts

Abstract

New spiroindolinone antagonists of CRTH2 are described. Following identification of insufficient stability in human plasma as an important liability of the lead compounds, replacement of the spirosuccinimide core with a spirohydantoin or spiropyrrolidinone structure has yielded a compound that is fully stable in human plasma and with good potency in a human whole blood assay (IC50 = 69 nM) but shows a much lower oral bioavailability (6-9% in rodents) than the earlier compounds. Successive optimization aimed at restoring an acceptable oral bioavailability has yielded compound (S)-17a, which exhibits both stability in human plasma and a good oral bioavailability in rat (37%) and mouse (39%). This compound is also active in a mouse model of ovalbumin-induced lung inflammation following oral dosing at 30 mg/kg.

References

14